Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Background The systematic reviews and meta-analyses performed until now did not provide the adequate picture of actual knowledge in the field of neuropsychiatric symptoms treatment using psychotropic cannabinoids in patients with Alzheimer disease (AD). The study question Which is the level of evidence, from quantitative and qualitative point of view, concerning the efficacy and safety of the treatment with psychotropic cannabinoids of neuropsychiatric symptoms in AD? Study design PubMed, EMBASE, Cochrane Database of Systematic Reviews, Google Scholar Data, and Clinicaltrials.gov were searched for randomized clinical trials with cannabinoids in Alzheimer dementia agitation and aggression. Measures and outcomes The rationale, the objectives, and the methods used for searching the trials have been established according to PRISMA Criteria 2009. Results The total number of patients in the 9 publications evaluated in this study, which included data from 6 clinical trials, was 422 patients-treatments, where treatment was a psychoactive cannabinoid or placebo, some of them obtained by multiplying selected patients with the number of cannabinoid treatments in the crossover studies. There are multiple sources of bias in the analyzed studies; 2 elements have prevented conclusive results. One element was polypragmazia, a major role being played by the use of psychotropic drugs other than cannabinoids, in an effort to reduce agitation and aggressive behavior. The second one was the large number of concomitant symptoms, for example, pain (commonly causing anxiety and agitation). Conclusions No clear conclusion can be drawn on the effectiveness of psychoactive cannabinoids in the treatment of psychiatric manifestations, in particular agitation and aggression, in AD. In the future, large randomized controlled trial with adequate designs, without crossover and for longer duration, adapted to cannabinoid pharmacokinetics, is required to establish the real efficacy and safety of these drugs in aggressive and/or agitated patients with AD.

What this study adds

Evidence grade: High

This is a trial of 422 participants. This review of six clinical trials of psychoactive cannabinoids for agitation and aggression in Alzheimer's dementia found multiple sources of bias and two factors that prevented conclusive results. Because of this, it cannot establish whether these cannabinoids are effective or safe for these symptoms.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Paunescu, H., Dima, L., Ghita, I., Coman, L., Ifteni, P. I., Fulga, I., et al. (2020). A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. American journal of therapeutics. https://doi.org/10.1097/mjt.0000000000001120

Vancouver

Paunescu H, Dima L, Ghita I, Coman L, Ifteni PI, Fulga I, et al. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. American journal of therapeutics. 2020. doi:10.1097/mjt.0000000000001120. PMID: 32118591.

BibTeX

@article{paunescu2020-32118591,
  author  = {Paunescu, H. and Dima, L. and Ghita, I. and Coman, L. and Ifteni, P. I. and Fulga, I. and Coman, O. A.},
  title   = {{A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia}},
  journal = {American journal of therapeutics},
  year    = {2020},
  doi     = {10.1097/mjt.0000000000001120},
  pmid    = {32118591},
  url     = {https://doi.org/10.1097/mjt.0000000000001120}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review of six clinical trials of psychoactive cannabinoids for agitation and aggression in Alzheimer's dementia found multiple sources of bias and two factors that prevented conclusive results. Because of this, it cannot establish whether these cannabinoids are effective or safe for these symptoms.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (American journal of therapeutics)
Journal's citation record 1 / 4 American Journal of Therapeutics: journal h-index 83 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question (from PubMed type “Systematic Review”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 2 / 4 422 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 3 / 7 Cited 19 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.4 citations a year over 8 year(s) since 2020
Impact for its field and year 1 / 6 Cited 0.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Oana Andreia Coman: h-index 11 (OpenAlex, whole career)
Institution's track record 0 / 3 Carol Davila University of Medicine and Pharmacy: institution h-index 304 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32118591)
Free to read 0 / 2 Behind a paywall — scores zero
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →